References
1. Asfandiyarova N.S. Risk factors for death in diabetes mellitus. Klinicheskaya meditsina [Clinical Medicine]. 2016; 94 (9): 697-700. (in Russian)
2. Dedov I.I., Shestakova M.V., Mayorov A.Yu. Algorithms for specialized medical care for patients with diabetes. Moscow: UP PRINT, 2019: 212 p. (in Russian)
3. Latypova E.A., Yamlikhanov A.G., Alieva N.M. Efficiency of treatment of diabetic patients with ocular complications at the ophthalmic center in Ufa. Meditsinskii vestnik Bashkortostana [Medical Bulletin of Bashkortostan]. 2018; 13 (1): 36-9. (in Russian)
4. Rajalakshmi R., Prathiba V., Mohan V. Does tight control of systemic factors help in the management of diabetic retinopathy? Indian J Ophthalmol. 2016; 64 (1): 62-8.
5. Mkrtumyan A.M., Shadrichev F.E. Diabetic Retinopathy: Is Prevention of Blindness Possible? Effektivnaya farmakoterapiya [Effective pharmacotherapy]. 2014; 46: 32-41. (in Russian)
6. Konenkov V.I., Klimontov V.V., Chernykh V.V., Tyan N.V. Anti-VEGF agents in the treatment of diabetic macular edema. Sakharnyi diabet [Diabetes Mellitus]. 2013; 4: 78-84. (in Russian)
7. Massin P., Bandello F., Garweg J.G., et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care. 2010; 33(11): 2399-405.
8. Nguyen Q.D., Shah S.M., Heier J.S., et al. Primary end point (six months) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology. 2009; 116 (11): 2175-81.
9. Nguyen Q.D., Shah S.M., Khwaja A.A., et al. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. Ophthalmology. 2010; 117 (11): 2146-51.
10. Sasongko M.B. WongT.Y. Nguyen T.T., et al. Serum apolipoproteins Al and В are stronger biomarkers of diabetic retinopathy than traditional lipids. Diabetes Care. 2011; 34: 474-9.
11. Simo R. Hernandez C. Fenofibrate for diabetic retinopathy. Lancet 2007; 370: 1667-8.
12. Wong T.Y., Simo R., Mitchell P. Fenofibrate - a potential systemic treatment for diabetic retinopathy? Am J Ophthalmol. 2012; 154 (1): 6-12.
13. Chew E.Y., Ambrosius W.T., Davis M.D., et al. ACCORD Study Group, ACCORD Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med. 2010; 363 (3): 233-44.
14. Mach F., Baigent C., Catapano A.L., et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019.
URL: https://www.portailvasculaire.fr/sites/default/files/docs/2019_esc-eas_dyslipidemie_guidelines.pdf
DOI: https://doi.org/10.1093/eurheartj/ehz455
15. Franssen R., Vergeer M., Stroes E.S., Kastelein J.J. Combination statin-fibrate therapy: safety aspects. Diabetes Obes Metab. 2009; 11 (2): 89-94.
16. Song J.H., Chin H.S., Kwon O.W., Lim S.J., et al. Effect of sulo-dexide in patients with non-proliferative diabetic retinopathy: diabetic retinopathy sulodexide study (DRESS). Graefes Arch Clin Exp Ophthalmol. 2015; 253 (6): 829-37.
17. Shestakova M.V., Shamkhalova M.Sh., Yarek-Martynova I.Ya., et al. Diabetes mellitus and chronic kidney disease: achievements, unsolved problems and treatment prospects. Sakharnyi diabet [Diabetes Mellitus]. 2011; 1: 81-8. (in Russian)
18. Batyushin M.M., Galushkin A.A., Litvinov A.S., et al. Place of sulo-dexide in renoprotective therapy of patients with chronic kidney disease. Meditsinskii vestnik Yuga Rossii [Medical Bulletin of the South of Russia]. 2012; 1: 72-3. (in Russian)
19. Masola V., Zaza G., Onisto M., et al. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014; 33 (3): 243-54.
20. Onuchin S.G., Onuchina E.L., Pozdnyak O.A., et al. Complex therapy of patients with diabetic foot syndrome and diabetic nephropathy using sulodexide: fixing the result. Prakticheskaya meditsina [Practical Medicine]. 2015; 86 (1): 107-13. (in Russian)
21. Shang H.X., Zhao J.Y., Shen X., et al. The efficacy and safety of sulodexide in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2016; 9 (7): 12481-91.
22. Coccheri S., Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2014; 8: 49-65.
23. Suchkova O.V., Rudnichenko V.A., Gurfinkel' Yu.I. Assessment of the relationship between microcirculatory disorders and diabetic polyneuropathy in type 2 diabetes mellitus. The factor of hyperglycemia in the development of vascular and neural disorders. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2017; 4:104-13. (in Russian)
24. Levin O.S., Chimagomedova A.Sh., Gan'kina O.A. Preparations of group vitamins in the treatment of diabetic polyneuropathy. Sovremen-naya terapiya v psikhiatrii i nevrologii [Modern Therapy in Psychiatry and Neurology]. 2017; 3: 21-6. (in Russian)
25. Agathos E., Tentolouris A., Eleftheriadou I., et al. Effect of a-lipoic acid on symptoms and quality of life in patients with painful diabeticneu-ropathy. J Int Med Res. 2018; 46 (5): 1779-90.
26. Varkonyi T., Korei A., Putz Z., et al. Advances in the management of diabetic neuropathy. Minerva Med. 2017; 108 (5): 419-37.
27. Garipova A.F., Saifutdinov R.G., Vagapova G.R. Clinical importance of monitoring the level of glycemia and ECG in patients with diabetes mellitus and stable angina. Dnevnik kazanskoi meditsinskoi shkoly [Diary of Kazan Medical School]. 2013; 1 (1): 86-7. (in Russian)
28. Krivoshchekov E. P., Elshin E. B., Romanov V. E. The results of treatment of diabetic foot syndrome modern dressings. Tavricheskij mediko-biologicheskij vestnik [Tauride Medical and Biological Bulletin]. 2017; 20 (3): 146-50. (in Russian)